ผลต่างระหว่างรุ่นของ "ผู้ใช้:Thomson Walt/กระบะทราย 4"
เนื้อหาที่ลบ เนื้อหาที่เพิ่ม
Thomson Walt (คุย | ส่วนร่วม) ลไม่มีความย่อการแก้ไข |
Thomson Walt (คุย | ส่วนร่วม) |
||
บรรทัด 30:
{{กล่องผู้ใช้ล่าง}}
=[[เอนเทรคทินิบ]]=
{{Use dmy dates|date=November 2019}}
{{Drugbox
| drug_name =
| INN =
| type =
| image = Entrectinib.svg
| width = 275
| alt =
| caption =
<!-- Clinical data -->
| pronounce =
| tradename = Rozlytrek
| Drugs.com = {{drugs.com|monograph|entrectinib}}
| MedlinePlus = a619049
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID = Entrectinib
| licence_US = Rozlytrek
| pregnancy_AU = D
| pregnancy_AU_comment = <ref name="Rozlytrek APMDS">{{cite web | title=Rozlytrek Australian prescription medicine decision summary | website=[[Therapeutic Goods Administration]] (TGA) | date=25 May 2020 | url=https://www.tga.gov.au/apm-summary/rozlytrek | access-date=16 August 2020}}</ref>
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_US_comment =
| pregnancy_category=
| dependency_liability =
| addiction_liability =
| routes_of_administration = [[Oral administration|By mouth]]
| class = Antineoplastic agent
| ATCvet =
| ATC_prefix = L01
| ATC_suffix = XE56 <!-- scheduled to be L01EX14 in 2021 -->
| ATC_supplemental =
<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = <ref name="Rozlytrek APMDS" />
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment = <ref>{{cite web | title=Rozlytrek 100 mg hard capsules - Summary of Product Characteristics (SmPC) | website=(emc) | url=https://www.medicines.org.uk/emc/product/11686/smpc | access-date=11 September 2020}}</ref>
| legal_US = Rx-only
| legal_US_comment = <ref name="Rozlytrek FDA label" />
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Rozlytrek EPAR" />
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment =
| legal_status = <!--For countries not listed above-->
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
<!-- Identifiers -->
| CAS_number = 1108743-60-7
| CAS_supplemental =
| PubChem = 25141092
| PubChemSubstance = 347828307
|
| DrugBank = DB11986
| ChemSpiderID = 24808589
| UNII = L5ORF0AN1I
| KEGG = D10926
| ChEBI =
| ChEMBL = 1983268
| NIAID_ChemDB =
|
| synonyms = RXDX-101, NMS-E628
<!-- Chemical and physical data -->
| IUPAC_name =
''N''-[5-(3,5-Difluorobenzyl)-1''H''-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-(tetrahydro-2''H''-pyran-4-ylamino)benzamide
| C=31 | H=34 | F=2 | N=6 | O=2
| SMILES = CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6
| StdInChI = 1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)
| StdInChI_comment =
| StdInChIKey = HAYYBYPASCDWEQ-UHFFFAOYSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
'''Entrectinib''', sold under the brand name '''Rozlytrek''', is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.<ref name="Rozlytrek FDA label" /> It is a selective [[tyrosine kinase inhibitor]] (TKI), of the [[tropomyosin receptor kinase]]s (TRK) A, B and C, C-ros oncogene 1 ([[ROS1]]) and [[anaplastic lymphoma kinase]] (ALK).<ref name="Rozlytrek FDA label" />
The most common side effects include tiredness, constipation, [[dysgeusia]] (taste disturbances), [[edema]] (swelling with fluid retention), [[dizziness]], [[diarrhea]], [[nausea]] (feeling sick), [[dysesthesia]] (unpleasant and abnormal feeling when touched), [[dyspnea]] (difficulty breathing), [[anemia]] (low red blood cell count), increased weight, increased blood creatinine (possible sign of kidney problems), pain, cognitive disorders (problems with ability to think, learn and remember), vomiting, cough, and fever.<ref name="Rozlytrek EPAR" /><ref name="FDA PR" />
It was approved for medical use in the United States in August 2019,<ref name="FDA PR">{{cite press release | title=FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor | website=U.S. [[Food and Drug Administration]] (FDA) | date=15 August 2019 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-third-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor | archive-url=https://web.archive.org/web/20190914141848/https://www.fda.gov/news-events/press-announcements/fda-approves-third-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor | archive-date=14 September 2019 | url-status=live | access-date=23 November 2019}} {{PD-notice}}</ref><ref>{{cite press release |title= FDA Approves Genentech's Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors | publisher = Genentech |url=https://www.gene.com/media/press-releases/14802/2019-08-15/fda-approves-genentechs-rozlytrek-entrec |website=Genentech |access-date=16 August 2019}}</ref><ref name="FDA approval">{{cite web | title=Drug Approval Package: Rozlytrek | website=U.S. [[Food and Drug Administration]] (FDA) | date=16 September 2019 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000TOC.cfm | access-date=23 November 2019}}</ref> in Australia in May 2020,<ref name="Rozlytrek APMDS" /> and in the European Union in July 2020.<ref name="Rozlytrek EPAR" />
==ดูเพิ่ม==
{{สถานีย่อยเภสัชกรรม}}
==อ้างอิง==
{{รายการอ้างอิง|2}}
{{กลุ่มยาหลัก}}
|